Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on April 28, 2022, primarily to disclose information related to its 2021 Annual Report filed with the Shanghai Stock Exchange and a significant clinical trial update. The company provided financial information prepared under China Accounting Standards (CAS), which differs from U.S. GAAP, along with details on R&D expenses and product inventory. Investors should note that this financial data is presented in accordance with PRC regulations and may require reconciliation for comparability with U.S. reporting standards.
Key Highlights
- 1BeiGene, Ltd. (the Company) filed its 2021 Annual Report with the Shanghai Stock Exchange, adhering to PRC listing rules and regulations.
- 2The STAR Annual Report includes detailed financial information prepared under China Accounting Standards (CAS), including gross profit margin, R&D expenses by product, and inventory levels for key products.
- 3The Company has provided supplemental information regarding R&D expenses and product inventory prepared under U.S. GAAP, along with a summary of material differences between PRC GAAP and U.S. GAAP, attached as Exhibit 99.1.
- 4The STAR Annual Report is available in Chinese on the Shanghai Stock Exchange website.
- 5An Independent Data Monitoring Committee (IDMC) determined that the global Phase 3 RATIONALE 306 trial for tislelizumab met its primary endpoint for overall survival (OS) in untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
- 6This positive Phase 3 result for tislelizumab in combination with chemotherapy is a significant clinical development for the company.